MAR 10, 2017 06:20 PM PST

Towards Effective Immunotherapy for Prostate Cancer

WRITTEN BY: Carmen Leitch

Prostate cancer is the most common type to afflict men; around 160,000 new cases are diagnosed in the United States every year. Roughly one in forty men will eventually die from the disease but it can also be treated successfully. New work by researchers at The University of Texas MD Anderson Cancer Center has identified a potential treatment for advanced prostate cancer that is resistant to castration therapy, which could be a major step forward in a disease that is hard to treat in advanced stages. A combination of immune checkpoint blockers along with therapeutics targeting cells of the immune system that are associated with bad outcomes and lack of response to treatment. Learn more about metastatic, castration-resistant prostate cancer in the following video.

A mouse model was created and utilized to test out this treatment, one which uses immune system blockades and takes aim at myeloid  myeloid-derived suppressor cells (MDSCs). MDSCs are a type of immune cell that are derived from bone marrow stem cells, which have powerful abilities to suppress the immune system and are also understood to have an influence in cancer metastasis and the formation of tumors. The work has been reported in the journal Nature.

"A significant number of advanced prostate cancer patients treated with a chemical castration therapy called androgen deprivation therapy (ADT) experience relapse with relentless progression to lethal metastatic, castration-resistant prostate cancer," explained Ronald DePinho, M.D., a Professor of Cancer Biology. "While immune checkpoint blockade therapy is effective in many cancers, it has been less successful for this particular form of prostate cancer, which has motivated a search for targeted therapies that overcome this resistance."

For this study, the investigators tried the immune checkpoint blockades anti-CTLA4 and anti-PD1 together, and obtained "modest efficacy," commented the first author of the report,  Xin Lu, Ph.D., who trained with DePinho and now works as an independent investigator at the University of Notre Dame. Another concept they tested utilized MDSC-inhibiting drugs like cabozantinib (Cabo) and BEZ, but again found insignificant anti-tumor effects. Then these treatments were tried in unison, however, a successful result was achieved.

"Strikingly, both primary and metastatic castration-resistant prostate cancer responded to a combined checkpoint blockade and MDSC targeted therapeutic approach," said DePinho. "These observations in mouse models of prostate cancer, using a sophisticated genetic approach developed by James Horner at MD Anderson, illuminate a clinical path hypothesis for combining immune checkpoint blockades with MDSC-targeted therapies in the treatment of this aggressive cancer."

DePinho noted that future work including clinical trials are required to confirm the findings as well as to investigate the effects of this combination therapy and selective anti-androgen drugs for cases of established prostate cancer that is  castration-resistant, in addition to new diagnosed cases to obtain "durable clinical response."

 

Soucres: American Cancer Society, AAAS/Eurekalert! via MD Anderson, Nature

About the Author
  • Experienced research scientist and technical expert with authorships on 28 peer-reviewed publications, traveler to over 60 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
OCT 21, 2019
Cancer
OCT 21, 2019
Don't Combine Breast and Gyno Surgery, Study Advises
Surgeries can be stressful and difficult for patients, and it’s understandable that some would want to reduce the number of days they need to devote...
OCT 21, 2019
Microbiology
OCT 21, 2019
A Canine Cancer That Began to Spread From One Dog About 6,000 Years Ago
Dogs can get different kinds of cancers, including one that is transmitted by live cancer cells, which spread through sexual contact....
OCT 21, 2019
Cell & Molecular Biology
OCT 21, 2019
Investigating the Molecular Basis of Sex-related Differences in Cancer
There are sex-specific differences in the rate and lethality of various cancers....
OCT 21, 2019
Cancer
OCT 21, 2019
Infant with leukemia saved by liver cancer drug
A young child just months old recently successfully received cancer treatment for an uncommon type of leukemia. The drug used in the treatment was not a ta...
OCT 21, 2019
Drug Discovery & Development
OCT 21, 2019
Evolutionary-Busting Cancer Drug
Researchers at the Institute of Cancer Research in London have discovered that a new type of drug that blocks treatment in cancers. The drug works by inhib...
OCT 21, 2019
Cardiology
OCT 21, 2019
What is Polycythemia Vera?
Polycythemia Vera (PV) is a slow-growing cancer of the blood. The cancer is characterized by an overproduction of blood cells within the bone marrow. Too m...
Loading Comments...